PROTEAN BIO INC.

Biotech · Private

D6PV, a novel ApoC-II peptide mimetic therapeutic for intravenous treatment of acute pancreatitis and severe hypertriglyceridemia

Grants
$3.0M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Development of D6PV- a novel ApoC-II peptide mimetic therapeutic$997,484
Federal grantDepartment of Health and Human Services · Phase II · Development of D6PV- a novel ApoC-II peptide mimetic therapeutic$997,746
Federal grantDepartment of Health and Human Services · Phase II · IND-enabling studies of D6PV- a novel ApoC-II peptide mimetic therapeutic$999,776
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2448Biohaven Pharmaceutical Holding Co Ltd.—$40M
2449Ionetix Corp—$38M
2450CALISTOGA PHARMACEUTICALS INC—$35M
2451PROTEAN BIO INC.——
2452PALM THERAPEUTICS, INC.——
2453ILLUMINATE THERAPEUTICS, INC.——
2454TERAPORE TECHNOLOGIES, INC.—$3.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Peptides For Beta-cell Survival And Insulin Productionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.